In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation

573 F. App'x 178
Court of Appeals for the Third Circuit·Decided July 14, 2014·No. 13-4548·Unpublished·Cited by 1 cases

Opinion

OPINION OF THE COURT

JORDAN, Circuit Judge.

Ruth Sanders appeals an order of the United States District Court for the Eastern District of Pennsylvania denying her recovery under the terms of the Diet Drug Nationwide Class Action Settlement Agreement (“Settlement Agreement”). We will affirm.

1. Background

This appeal relates to the settlement of multi-district products liability litigation regarding the diet drugs Pondimin® and Redux®, previously sold by American Home Products Corporation (“AHP”). See In re Diet Drugs Prods. Liab. Litig., 543 F.3d 179, 180-81 (3d Cir.2008). In November 1999, Wyeth, the successor-in-interest to AHP, joined plaintiffs’ representatives in the Settlement Agreement, which the District Court approved. See id. at 181. Under the terms of the Settlement Agreement, Wyeth was required to contribute funds, placed in a trust, for the payment of claims. See id. at 180. The resulting AHP Settlement Trust (the “Trust”), acting through its trustees and claims administrator, administers and reviews claims to determine the benefits, if any, that a class member is qualified to receive under the terms of the Settlement Agreement. See id. 1

Sanders, 2 a class member, sought compensation benefits under the Settlement *180 Agreement. She based her claim on an echocardiogram performed in 2002 after she had ingested Pondimin for 240 days. Having reviewed the echocardiogram, an attesting physician, Dr. Howard Brazil, attached an affidavit (the “Green Form”) to her claim, in which he stated that she has “moderate mitral regurgitation” (Trust Supp.App. at 19), meaning the heart valve separating her upper and lower heart chambers fails to close properly, causing leakage. Under the Settlement Agreement, moderate mitral regurgitation is one of the qualifying medical conditions for compensation. 3 Upon initial review, the Trust’s auditing cardiologist agreed that there was a “reasonable medical basis” 4 to support Dr. Brazil’s representations and that Sanders’s claim was potentially payable. (Trust Supp.App. at 34.)

Unfortunately, the Trust was inundated with fraudulent claims that included manipulated echocardiogram test results. See In re Diet Drugs, 543 F.3d at 182 n. 4. In light of that problem, and during the pendency of Sanders’s claim, the Seventh Amendment to the Settlement Agreement was agreed to and implemented. The Seventh Amendment provided two options to claimants who had not yet received post-audit approval and whose claims indicated signs of material misrepresentation: either participate in new procedures, including additional medical reviews of submitted evidence or opt out of the Settlement’s Seventh Amendment and have their claims re-audited “to determine whether there were any intentional material misrepresentations made in connection with the Claim.” (App. at A5.) Sanders’s claim fell within the scope of the Seventh Amendment, and she chose the latter option. On March 6, 2007, the Trust issued a determination letter rejecting Sanders’s claim based on substantial evidence of intentional material misrepresentation. The letter included a declaration of another auditing cardiologist, Dr. Joseph Kisslo, who, in addition to agreeing with the Trust’s ultimate determination of intentional misrepresentation, concluded that there was no reasonable medical basis for finding moderate mitral regurgitation based on Sanders’s echocar-diogram.

Sanders, disagreeing with that determination, submitted a Notice of Contest of Post Audit Determination pursuant to Audit Rule 18 of the Settlement Agreement. She attached a supplemental affidavit from Dr. Brazil, as well as affidavits from the owner of the company that performed the echocardiogram and a sonog-rapher, all attesting that the echocardio-gram was performed according to the Settlement Agreement’s criteria. After reviewing those additional materials, the Trust reaffirmed in a Final Post Audit Determination that it would deny Sanders compensation benefits, because of substantial evidence of intentional material misrepresentations.

*181 Sanders formally disputed the Trust’s Final Post Audit Determination, and the Trust subsequently applied to the District Court to require Sanders to show cause why her claim should be paid. The District Court issued a show-cause order to Sanders and referred her claim to a Special Master, who in turn appointed a Technical Advisor, Dr. Gary Vigilante, to review the claim. Dr. Vigilante issued a Technical Advisor Report, as required by the Settlement Agreement. In the report, Dr. Vigilante agreed with Dr. Kisslo that there was no reasonable medical basis for Dr. Brazil’s finding of moderate mitral regurgitation. He also agreed that the echo-cardiogram study “was not conducted in a manner consistent with medical standards.” (Trust Supp.App. at 167.) Sanders responded to Dr. Vigilante, arguing that there could be no “intentional material misrepresentation” in connection with Sanders’s claim because four different cardiologists were able to render an opinion on the echocardiogram. (Trust Supp.App. at 172.)

The show-cause record, including Dr. Vigilante’s report and the parties’ statements of the ease, was then submitted to the District Court. After reviewing the record, the Court found that Sanders had failed to meet her burden of proving that a reasonable medical basis existed to support her claim. It declined to reach the misrepresentation issue. The Court thus affirmed the Trust’s denial of her claim. Sanders timely appealed.

II. Discussion 5

On appeal, Sanders brings six arguments, only two of which warrant more than passing discussion: first, that the evidence in the record met the burden of proof for establishing a reasonable medical basis for Dr. Brazil’s Green Form, and, second, that the Court erred by deputizing the Technical Advisor with judicial power. Both arguments are unpersuasive. 6

The District Court’s determination was not an abuse of discretion. “The test is not what this court would have done under the same circumstances; that is not *182 enough. We must feel that only one order could have been entered on the facts.” In re Orthopedic Bone Screw Prods. Liab. Litig., 246 F.3d 315, 320 (3d Cir.2001) (quotation marks omitted) (quoting In re Gypsum Antitrust Cases, 565 F.2d 1123, 1128 (9th Cir.1977)). Sanders fails to show that the only conclusion that could be drawn from her echocardiogram is that she suffered from moderate mitral regurgitation. As the District Court noted, she failed to rebut the opinions of Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation, 573 F. App'x 178 (3d Cir. 2014).

573 F. App'x 178 (In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related